PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer

Abstract

Abnormal expression or mutation of RNA splicing proteins are widely observed in human cancers. Here, we identified poly(U) binding splicing factor 60 (<i>PUF60</i>) as one of the most differentially expressed genes out of 97 RNA splicing proteins between normal and bladder cancer tissues by bioinformatics analysis of TCGA bladder cancer expression data. The expression of <i>PUF60</i> was significantly higher in tumor tissues, while high <i>PUF60</i> expression was associated with malignant phenotypes of bladder cancer and shorter survival time. Moreover, we identified aurora kinase A (<i>AURKA</i>) as a new downstream target of <i>PUF60</i> in bladder cancer cells. <i>PUF60</i> knockdown significantly inhibited cell viability and colony formation capacity in bladder cancer cells, whereas <i>AURKA</i> overexpression reversed this inhibition effect. Overexpression of <i>PUF60</i> significantly promoted cell viability and colony formation in bladder cancer cells, while treatment with <i>AURKA</i> specific inhibitor reversed this promotive effect. Mechanistically, <i>PUF60</i> specifically bound to the <i>AURKA</i> promoter, thereby activating its transcription and expression. Furthermore, we showed that there was a significant positive correlation between <i>PUF60</i> and <i>AURKA</i> expression in bladder cancer tissues, and <i>PUF60</i> and <i>AURKA</i> expression contributed to tumor progression and malignant phenotypes in the patients with bladder cancer. Collectively, these results indicate that the <i>PUF60/AURKA</i> axis plays a key role in regulating tumorigenesis and progression of bladder cancer, and may be a potential prognostic biomarker and therapeutic target for bladder cancer patients.